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Despite  the  great  clinical  signiﬁcance  of radiation-induced  cardiac  damage,  experimental  investigation  of
its  mechanisms  is  an unmet  need  in  medicine.  Beneﬁcial  effects  of growth  hormone-releasing  hormone
(GHRH)  agonists  in  regeneration  of the  heart  have  been  demonstrated.  The  aim  of this  study  was  the
evaluation  of  the potential  of modern  GHRH  agonistic  analogs  in prevention  of radiation  damage  in an  in
vitro cardiac  myocyte-based  model.
Cultures of  cardiac  myocytes  isolated  from  newborn  rats  (NRVM)  were  exposed  to  a  radiation  dose  of
10 Gy.  The  effects  of  the  agonistic  analogs,  JI-34  and  MR-356,  of  human  GHRH  on  cell  viability,  prolifera-
tion,  their  mechanism  of action  and  the  protein  expression  of  the  GHRH/SV1  receptors  were  studied.
JI-34  and  MR-356,  had  no  effect  on  cell  viability  or proliferation  in unirradiated  cultures.  However,  in
irradiated  cells  JI-34  showed  protective  effects  on cell  viability  at concentrations  of 10  and  100  nM, and
MR-356 at  500  nM;  but  no  such  protective  effect  was detected  on cell  proliferation.  Both  agonistic  analogs
decreased  radiation-induced  ROS  level  and JI-34 interfered  with  the  activation  of SAFE/RISK  pathways.
Using  Western  blot  analysis,  a  52  kDa  protein  isoform  of GHRHR  was  detected  in the  samples  in  both
irradiated  and  unirradiated  cells.
Since GHRH  agonistic  analogs,  JI-34  and  MR-356  alleviated  radiation-induced  damage  of  cardiac
myocytes,  they  should  be  tested  in  vivo as potential  protective  agents  against  radiogenic  heart  damage.
© 2016  Elsevier  Ltd. All  rights  reserved.. Introduction
Radiation-induced heart diseases including ischemic heart dis-
ase, congestive heart failure, electrical conduct defects and valve
bnormalities are typically late consequences of radiotherapy,
ccurring many years or decades after treatment [1,2]. Such adverse
ffects may  develop after chest irradiation in childhood cancers,
ung, esophageal or breast cancer or Hodgkin’s lymphoma [3,4].
hese often unattributed complications cause deterioration in
uality of life of long-surviving patients, extra health care costs,
∗ Corresponding author at: Cardiovascular Research Group, Department of Bio-
hemistry, University of Szeged Dóm tér 9, Szeged, H-6720, Hungary.
E-mail address: aniko.gorbe@pharmahungary.com (A. Görbe).
1 Both authors contributed equally.
ttp://dx.doi.org/10.1016/j.phrs.2016.07.036
043-6618/© 2016 Elsevier Ltd. All rights reserved.and lead occasionally to fatal outcomes. Although the application of
modern radiotherapy planning and delivery signiﬁcantly improves
the radiation protection of the heart, in many cases, the entire heart
or a part of it still receives a dose sufﬁcient to cause long-term
adverse effects. Notably, the evolving use of intensity-modulated
radiotherapy (IMRT) will increase the volume of non-target tissues
irradiated with low dose.
The development of radiation-induced heart diseases is dose-
dependent, and is more likely if radiation exposure occurs at
a younger age [5,6]. Radiogenic ischemic heart disease, due to
atherosclerotic changes of the coronary arteries, is indistinguish-
able from other etiologies that cause angina or myocardial infarct.
Robust epidemiological data on such cardiovascular disease origi-
nates from breast cancer studies. Darby et al., analyzing the SEER
database of more than 300,000 patients, found that among those
8 gical Research 111 (2016) 859–866
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Table 1
Cell survival in function of radiation dose. The 24-h cultures were exposed to differ-
ent  radiation doses (5, 10, 15, 20 Gy), and cell loss was detected at different latency
times (0, 24, 48, 72, 96, 120 h). Data are expressed in percent of unirradiated control
(mean ± SEM).
Cell survival in ratio to control (%)
Time after irradiation 5 Gy 10 Gy 15 Gy 20 Gy
0 h 100 ± 2 98 ± 2 95 ± 2 96 ± 3
24 h 76 ± 2 75 ± 3 79 ± 4 89 ± 6
48 h 63 ± 2 50 ± 2 43 ± 1 44 ± 160 L. Kiscsatári et al. / Pharmacolo
ho received adjuvant radiotherapy, the patients with left sided
umors had a signiﬁcantly increased risk of cardiac death due
o cardiovascular diseases or myocardial infarction, appearing 10
ears after the irradiation, and increasing further thereafter [7,8]. It
eems likely, that the radiogenic damage of the macrovasculature
f the heart occurs after the exposure of these structures to rela-
ively high doses. Animal experiments revealed inﬂammatory and
xidative damage leading to the formation of typical atheroscle-
otic plaques [4,9]. Radiation-induced diffuse myocardium changes
nclude microvasculature abnormalities, degenerative cardiomy-
cyte and interstitial ﬁbrotic changes. Such abnormalities may
evelop after even low dose radiation exposure, and can result
n the deterioration of the heart’s pump function or in cardiac
onduction abnormalities [10]. Cilliers et al., investigated radiation-
nduced time-dependent changes of the myocardium in Wistar
ats [11]. Interestingly, the radiation induced structural changes
f the endothelial cells and myocytes developed early after the
rradiation, and were accompanied by a transitory depression of
he mechanical function of the heart; 100–180 days after the irra-
iation, only interstitial inﬂammation and ﬁbrosis were present.
adiation induces inﬂammatory responses, and activates senes-
ence pathways; there is a need to test new agents that could
revent these cellular responses.
Growth hormone-releasing hormone (GHRH) was  ﬁrst iden-
iﬁed in humans as a hypothalamic peptide hormone which
rimarily regulates the production and release of pituitary growth
ormone (GH) [12]. Recently, the expression of GHRH has also been
emonstrated in a series of normal and cancerous tissues [13]. The
ituitary receptor of GHRH (pGHRHR) belongs to the class type-II G
rotein-coupled receptors [14] the binding induces the production
f cAMP that triggers a series of intracellular signaling cascades.
he presence of its splice variants (mainly SV1, less importantly
V2, SV3) has been demonstrated in a series of peripheral nor-
al  tissues and a variety of cancers [15–17]. Stimulation of the
HRHR results in the activation of the ERK1/2, AKT, JAK2/STAT3,
I3K/AKT pathways [18]. Numerous experimental data support
he autocrine-paracrine role of the GHRH system in regeneration
f tissue. GHRH has been shown to promote survival and inhibit
poptosis in cardiomyocytes in vitro despite serum starvation or
soproterenol treatment [19]. The expression and activation of
GHRHR after GHRH administration were demonstrated in both
dult rat ventricular myocytes and in H9c2 embryonic rat heart
ells, which expressed pGHRHR [20].
GHRH prevented death of adult rat cardiac myocytes induced
y serum starvation or by isoproterenol treatment which was
ntagonized by antagonistic analog of GHRH, JV-1-36. These pro-
ective effects were mediated by the activation of the extracellular
ignal −regulated kinase (ERK)1/2 and phosphoinositide-3 kinase
PI3K)/Akt signaling pathways. Additionally, isolated rat hearts
ubjected to ischemia-reperfusion (I/R) injury were protected by
he administration of GHRH before ischemia, which was  abolished
f co-administered with JV-1-36 [19]. Penna at al. demonstrated
imilar results in the isolated rat heart model; the administration of
HRH at the onset of reperfusion reduced the size of the infarct, and
his effect was abrogated if antagonistic analog of GHRH, JV-1-36
as co-administered [21].
Kanashiro-Takeuchi demonstrated that the administration of
he GHRH agonist, JI-38, reversed ventricular remodeling and
nhanced functional recovery after myocardial infarction, while
educing experimental infarct size in rats [22]. These effects were
bsent if a GHRH antagonist was co-administered, or by treatment
ith GH only. These effects point to the role of a GHRHR-mediated
echanism.
Following the demonstration of beneﬁcial results of the J.I. class
f agonistic analogs of GHRH in multiple ﬁelds, new classes of GHRH
gonists have been developed with the ultimate goal of clinical use72 h 58 ± 3 49 ± 3 43 ± 3 42 ± 2
96 h 71 ± 7 78 ± 8 53 ± 3 49 ± 3
120 h 50 ± 2 38 ± 1 37 ± 1 39 ± 2
[23]. As noted some of them have been tested in the experimental
myocardial infarct rat model, which conﬁrmed the cardioprotective
effects of GHRH agonists by measurement of infarct size and heart
function [23,24].
Since radiation triggers similar mechanisms as other cellular
stresses, such as starvation and hypoxia, we hypothesized that
GHRH and its receptor(s) might have a role in the recovery after
irradiation. We therefore set out to study the effects of GHRH and its
agonistic analogs in vitro, in newborn rat cardiomyocytes (NRVM),
under different conditions.
2. Materials and methods
These experiments conform the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-
23, Revised 1996) and was approved by the local ethics committee
at the University of Szeged.
2.1. Preparation of cultures of primary neonatal rat cardiac
myocytes
Neonatal rat cardiac myocytes (NRVM) were isolated as previ-
ously described [25]. Brieﬂy, newborn Wistar rats were disinfected
with 70% ethanol and then killed by cervical dislocation. Hearts
were excised and transferred to cold phosphate-buffered saline
(PBS), pH 7.2. The ventricles were separated, minced gently by ﬁne
forceps and digested in 0.25% trypsin solution (5 ml/heart) at 37 ◦C
for 25 min. The cell suspension was  then centrifuged at 2000 RPM at
4 ◦C for 15 min. Pellets were resuspended in growth medium (Dul-
becco’s MEM  supplemented with 10% fetal bovine serum [FBS], 0.1%
glutamine, 0.1% Antibiotic/Antimycotic solution) and plated onto 6-
well plates to eliminate ﬁbroblasts at 37 ◦C for 90 min  (pre-plating
step). Cells of the supernatant were then re-plated onto fresh 6- and
96-well plates and ﬂasks (5 × 105, 15 × 104 and 4 × 106 cells/well,
respectively). NRVM were supplied with 2 ml,  150 l and 20 ml  per
well growth medium with or without 10% FBS in 6-well, 96-well
plates and ﬂasks, respectively, and were incubated at 37 ◦C and 5%
CO2. The experiments were started 24 h after plating.
2.2. Irradiation of cell cultures
The cell cultures were irradiated 24 h after plating, using a linear
accelerator (Siemens Primus, Siemens Medical Solutions, USA). The
plates were irradiated with 6 MV  energy photon beams with oppos-
ing ﬁeld technique. To achieve a homogeneous dose distribution in
the sample, 2 cm thick PMMA  sheets were applied.
2.3. Testing of GHRH agonist treatmentFirst, the effects of synthetic human GHRH (hGHRH) (Bertin
Pharma, Montigny le Bretonneux, France) was tested at concen-
trations of 1, 10, 50, and 100 nM in unirradiated and irradiated cell
L. Kiscsatári et al. / Pharmacological Research 111 (2016) 859–866 861
Fig. 1. Viability of unirradiated (A) and irradiated (B) NRVM after hGHRH treat-
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Fig. 2. Viability of unirradiated (A) and irradiated (B) NRVM after JI-34 treatment
(48  h). Bromodeoxyuridine (BrdU) proliferation assay performed in unirradiated (C)ent (48 h). The effects of hGHRH on the proliferation of unirradiated and irradiated
RVM are shown in panels C and D, respectively. Data are expressed as mean ± SEM
n  comparison to control (100%); * p < 0.05, n = 8–16 in each group.
ultures. Next, GHRH agonists, JI-34 and MR-356, were studied both
n unirradiated and irradiated cell cultures at concentrations of 1,
0, 50, 100 and 500 nM in cultures with or without 1% FBS supple-
entation (for JI-34). Cell viability and proliferation assays were
erformed 48 h thereafter.
NRVM cultures maintained in FBS-supplemented medium were
lso studied for GHRHR expression and possible involved signaling
athways via Western blot analyses as follows: 1. non-irradiated,
on-treated, 2. non-irradiated, JI-34-treated, 3. irradiated, non-
reated, 4. irradiated and JI-34-treated; in these experiments, JI-34
as applied at the most effective concentration of 10 nM.  Cells were
ollected 1 and 48 h after the irradiation.
.4. Cell viability and proliferation assays
Both tests were performed following the respective experimen-
al procedure (irradiation and/or treatment). For the assessment
f cell viability, NRVM were incubated with 1 M calcein ace-
oxymethyl ester (calcein-AM, Sigma, St Louis, MO)  at room
emperature for 30 min. Fluorescence intensity was  measured with
 ﬂuorescence plate reader (Fluostar Optima, BMG  Labtech, Orten-and irradiated NRVM (D), 48 h after the treatment with JI-34. Data are expressed
as  mean ± SEM; in comparison to unirradiated untreated control (100%). * p < 0.05,
n  = 8–16 in each group.
berg, Germany) [26]. Cell viability was compared to that of vehicle
control. Each plate contained non-irradiated columns serving as
technical controls.
For the assessment of cell proliferation the NRVM cultures were
incubated and labeled with 10 l/well 5-bromo-2′-deoxyuridine
(BrdU) (Cell Proliferation ELISA, BrdU (colorimetric), Roche,
Germany) labeling solution at 37 ◦C, 5% CO2 for 20 h. Then the
labeling medium was removed, the cells ﬁxed, and the DNA was
denatured in one step with ﬁx/denature solution. Then an anti-
BrdU mouse monoclonal antibody was added followed by an HRP
conjugated secondary antibody to detect the incorporated BrdU.
The absorbance intensity was measured with a plate reader.
2.5. Western blot
After the indicated time of incubation, cell cultures were washed
with D-PBS and incubated for 5 min  in homogenization buffer (1 x
RIPA supplemented with a protease and phosphatase inhibitor
cocktail). Then cells were scraped, collected and sonicated with
an ultrasound homogenizer for 10 s on ice. The homogenate
was centrifuged at 11800 RPM, 4 ◦C for 10 min (Hettich Univer-
sal 320 R Centrifuge, Andreas Hettich GmbH and Co., Tuttlingen,
862 L. Kiscsatári et al. / Pharmacological Research 111 (2016) 859–866
Fig. 3. NRVM cell viability cultured with or without 1% FBS. Unirradiated and irra-
diated cultures were compared after 48 h of latency time (A). Viability of irradiated
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Fig. 4. Viability of unirradiated (A) and irradiated (B) NRVM after MR-356 treatment.
Bromodeoxyuridine (BrdU) proliferation assay performed in unirradiated (C) andrcm NRVM cells after JI-34 treatment, cultured without FBS supplementation; data
re  expressed as mean ± SEM; in comparison to control (100%). * p < 0.05, n = 8–16
n  each group (B).
ermany); the supernatant was transferred into a concentrating
ube (Amicon® Ultra-4 Centrifugal Filter Units, 10 kDa MWCO),
nd was centrifuged again at 6300 RPM, 4 ◦C for 20 min. The
oncentrated sample was collected and stored at −80 ◦C. Protein
oncentration was measured with bicinchoninic acid (BCA) assay
PierceTM BCA Protein Assay Kit, Thermo Fisher Scientiﬁc Inc.,
altham, MA  USA) by reading the optical density at UV max  of
60 nm,  and calculating automatically by the Anthos software.
For analysis of GHRHR expression 20-g samples of protein
ere loaded on 10% SDS-PAGE followed by the transfer of pro-
eins onto a nitrocellulose membrane (90 V, 1 h). Membranes
ere then blocked overnight at 4 ◦C in 1% bovine serum albu-
in  (BSA). Membranes were incubated both with GHRHR antibody
1:1000, ab76263, Abcam Inc., Cambridge, MA)  and GAPDH anti-
ody (1:5000, Cell Signaling Technology, Danvers, MA)  for 1.5 h
t room temperature in 1% BSA (Cell Signaling Technology, Dan-
ers, MA)  and then anti-rabbit HRP secondary antibody (1:2000;
:10000, Dako, Glostrup, Denmark) for 40 min. Membranes were
hen developed with an enhanced chemiluminescence kit (GE
ealthCare, Little Chalfont, UK), exposed to X-ray ﬁlm (Kodak,
ochester, NY, US), and scanned [27].
For the analysis of ERK and Akt, equal amounts of protein
20 g) were mixed with reducing 5 × Laemmli buffer, loaded
nd separated in 4–20% precast Tris-glycine SDS polyacrilamide
els (Bio-Rad Hungary Ltd., Budapest, Hungary). Proteins were
ransferred onto a polyvinylidene diﬂuoride membrane (Bio-Rad
ungary Ltd., Budapest, Hungary) at 350 mA  for 2 h. Transfer was
isualized with Ponceau staining (Sigma, St Louis, MO). Mem-
ranes were blocked with 5% BSA (Santa Cruz Biotechnology,
nc., Heidelberg, Germany) in Tris-buffered saline containing 0.05%
ween-20 (0.05% TBS-T; Sigma, St Louis, MO)  at room temperature
or 2 h. Membranes were probed with primary antibodies (dilution
:1000) overnight at 4 ◦C (phospho-Akt [Ser473] – #9271; Akt –
9272; phospho-Erk1/2 [Thr202/Tyr204] – #9106; Erk1/2 – #9107;irradiated NRVM (D) 48 h after the treatment with MR-356. Data are expressed as
mean ± SEM; in comparison to control (100%). * p < 0.05, n = 8–16 in each group.
GAPDH – #5174), and with corresponding HRP-conjugated sec-
ondary antibodies (Cell Signaling Technology, Danvers, MA)  for 2 h
at room temperature. Signals were detected with the chemilumi-
nescence kit. Quantiﬁcation was made by intensity ratio by Image
Lab 4.1 (Image LabTM Software, Bio-Rad Laboratories, Inc., Cali-
fornia, USA). Antibodies detecting phosphorylated epitopes were
removed with Pierce stripping buffer (Thermo Scientiﬁc Labor Kft.,
Budapest, Hungary) before incubation with antibodies detecting
the total protein.
2.6. Oxidative stress detection
The presence of superoxide was detected with a plate reader
using the oxidative ﬂuorescent dye dihydroethidium (DHE)
(Sigma St. Louis, MO;  D7008). Cell membranes are freely perme-
able to DHE that ﬂuoresces red when oxidized to ethidium in the
presence of superoxide. The presence of general ROS production
was detected by DCFH-DA (Sigma; D6883). Cardiac myocytes were
rinsed with PBS, then incubated with 10 uM DHE or DCFH-DA at
room temperature for 60 min  in a dark chamber, After removing
L. Kiscsatári et al. / Pharmacological Research 111 (2016) 859–866 863
Fig. 5. Western blot analysis: pGHRHR and GAPDH housekeeping gene expression
(A). The expression of GHRHR normalized to the GAPDH housekeeping gene in
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Fig. 6. The expression of pERK/ERK and the expression of GAPDH housekeeping
gene in unirradiated and irradiated NRVM cultures. Western blots were performed
both on untreated cells and cells treated with 10 nM JI-34. Results are mean ± SEM;
n  = 6 sample/group *p < 0.05.
Fig. 7. The expression of pAkt/Akt and the expression of GAPDH housekeeping gene
in  unirradiated and 10 Gy irradiated NRVM cultures. Western blots were performednirradiated (B) and irradiated (C) NRVM cultures. Western blots were performed
oth on untreated cells and cells treated with 10 nM JI-34. Results are mean ± SEM
expressed in% as compared to non-treated cells); n = 6 sample/group, *p < 0.05.
xtra dye with D-PBS (pH 7.4), the ﬂuorescence intensity was mea-
ured [28].
.7. Statistical analysis
Results are presented as a mean ± SE. One-way analysis of vari-
nce (ANOVA) followed by Fisher’s least signiﬁcant difference (LSD)
ost-hoc tests or Dunnet’s post-hoc tests were used to evaluate dif-
erences between groups. Two experimental groups were analyzed
ith the t-test. Western blot results were analyzed with two-way
nalysis of variance (ANOVA). Differences were considered signiﬁ-
ant if p < 0.05.. Results
To determine optimal experimental conditions, NRVM were
xposed to various radiation doses, and viability was measured fol-both on untreated cells and cells treated with 10 nM JI-34. Results are mean ± SEM;
n  = 6 sample/group *p < 0.05.
lowing varying latency times (Table 1). A signiﬁcant cell loss of 50%
was obtained after 10 Gy dose of radiation and latency time of 48 h.
This set of conditions was  chosen and applied throughout all the
experiments.
864 L. Kiscsatári et al. / Pharmacological Research 111 (2016) 859–866
Fig. 8. ROS production in ratio of viability (A) detected 48 h postirradiation. The effect of JI-34 on ROS formation in unirradiated (B) and irradiated NRVM (C); the effect
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Hf  MR-356 on ROS production in unirradiated (D) and irradiated cells (E). The supe
uperoxide levels in unirradiated (G) and irradiated NRVM (H); the effect of MR-356
 = 8–16 in each group *p < 0.05.
First, the effect of hGHRH was tested on cell viability and cell
roliferation in unirradiated and irradiated NRVM cultures. hGHRH
id not signiﬁcantly inﬂuence cell survival as compared to control
Fig. 1A and B). hGHRH was tested for its effect on cell proliferation
ia the BrdU incorporation assay. Cell proliferation of both irradi-
ted and non-irradiated cells was slightly stimulated by hGHRH at
 concentration of 50 nM (Fig. 1C).
The effects of the GHRH agonists, JI-34 and MR-356, were ﬁrst
ested in unirradiated NRVM. The administration of JI-34 had no
ffect on cell viability at concentrations of 1–500 nM (Fig. 2A).
owever, in irradiated cells, JI-34 showed a protective effect ate level in ratio of viability detected 48 h after irradiation (F). The effect of JI-34 on
peroxide level in unirradiated (J) and irradiated NRVM (I). Results are mean ± SEM;
concentrations of 10 and 100 nM (Fig. 2B). Anti-proliferative effect
of JI-34 was  detected at 50 nM in unirradiated and at 1–50 nM in
irradiated cultures (Fig. 2C and D). We  have tested the same param-
eters under serum-deprived conditions to test the possible effects
of the absence of 1% FBS including the avoidance of the binding of
the analogs to the plasma proteins. NRVM cultures maintained in
serum-free medium for 2 days contained roughly 50% less cells both
in the irradiated and unirradiated plates (Fig. 3A). Again, a strong
protective effect of JI-34 was  detected after irradiation, at concen-
trations of 10 and 100 nM (Fig. 3B). The GHRH agonist, MR-356, had
no signiﬁcant effect on cell survival in unirradiated NRVM cultures
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Fig. 4A), but prevented cell loss at a concentration of 500 nM after
rradiation (Fig. 4B). No proliferative effect of MR-356 was  detected
n either the unirradiated or the irradiated cultures (Fig. 3C and D).
In order to investigate the expression of GHRHRs in NRVM at the
rotein level, Western blot analysis was performed using an anti-
ody able to detect pGHRHRs. A 52 kDa protein isoform was readily
etected in the samples together with GAPDH used as internal con-
rol (Fig. 5A). This 52 kDa glycosylated GHRHR was  expressed in
oth irradiated and unirradiated cells. The treatment of cells with
I-34, did not inﬂuence the expression of GHRHRs (probably due to
ow dose of agonist) in irradiated (Fig. 5B) or unirradiated NRVM
Fig. 5C). Irradiation caused signiﬁcant decline in receptor expres-
ion after 48 h
For further investigation of intracellular action of GHRH ago-
ists, the activation of RISK/SAFE pro-survival kinases was tested.
he phosphorylation ratio of ERK signiﬁcantly increased after the
rradiation with 10 Gy, which was signiﬁcantly attenuated by JI-
4 treatment (Fig. 6). Likewise, the phosphorylation ratio of AKT
igniﬁcantly increased after the 10-Gy irradiation which was sig-
iﬁcantly attenuated after JI-34 treatment (Fig. 7).
Next, JI-34 agonist was additionally tested for its possible effect
n ROS production. Both the overall level of ROS and that of
uperoxide signiﬁcantly increased 48 h after the irradiation. JI-34
reatment signiﬁcantly decreased overall ROS production after irra-
iation, while MR-356 decreased its level in both irradiated and
nirradiated cultures. Both agonists decreased superoxide level sig-
iﬁcantly in irradiated cultures (Fig. 8).
. Discussion
In this in vitro NRVM model, the agonistic analogs of GHRH, JI-
4 and MR-356, reduced radiation-induced cell loss. This is the ﬁrst
emonstration that GHRH agonists exert protective effect in irra-
iated cardiac myocytes via the attenuation of ROS formation and
ther mechanisms present in different kinds of stress situations.
hese data and the expression of GHRHR in NRVM contribute to the
revious ﬁndings on the role of the GHRH system in cardiomyocyte
egeneration. Radiogenic late cardiac cytotoxicity is widely-studied
n in vivo models, however, limited experience is available with the
se of in vitro models appropriate for the study of acute radiogenic
ffects. The present study seems to provide reproducible conditions
or further studies.
The mechanism of cardiocytoprotection of GHRH agonists is not
ully clariﬁed, and probably depends on the system examined. The
ntiapoptotic effects of GHRH agonists have been demonstrated in
n vivo experimental infarcts in the rat. The chronic administra-
ion of the GHRH-agonist JI-38 upregulated the expression of the
nti-apoptotic BCL2, while down-regulated that of the proapop-
otic BAX gene, and increased the proliferation of cardiac precursor
ells in experimental heart infarcts [22,24]. In a similar system,
HRH agonists reduced the expression of inﬂammatory and pro-
brotic markers [20]. In H9c2 cardiomyoblasts cultured under
erum-deprived condition, agonistic analogs of GHRH repressed
he expression of a series of genes related to cardiac remodelling
20]. Some studies conclude to that GHRH or its agonistic analogs
odulate the kinases included in the RISK and SAFE pathways
19,21]. GHRH treatment prevented apoptosis induced by serum
tarvation or isoproterenol treatment in cardiac myocytes through
he interaction with multiple signalling mechanisms involving the
AMP/protein kinase A, ERK ½ and PI3K/Akt pathways [19]. GHRH
rotected the rat heart from I/R-caused injury administered at
eperfusion via activation of the RISK and SAFE pathways, as mea-
ured 20 min  after the start of reperfusion [21]. The early activation
f ERK 1/2 and Akt was  detected by Granata, in serum-deprived
solated cardiac myocytes [19]. In our study, the post-irradiationResearch 111 (2016) 859–866 865
administration of GHRH agonists also strongly affected the activa-
tion of the SAFE/RISK signaling pathways. Both JI-34 and MR-356
treatment signiﬁcantly decreased phosphorylation of Akt and ERK
after 48 h of latency time. Their protective effect may be explained
by this phenomenon since irradiation induces the MAPK pathway
and the phosphorylation of ERK via ROS formation [29]. In fact,
our study indicates that the agonistic analogs of GHRH directly
inﬂuence oxidative stress. ROS formation readily detectable 48 h
after the irradiation was effectively reduced by the post-irradiation
administration of JI-34 and MR-356. The pretreatment of C3H mice
with the GHRH antagonist, JMR-132, caused a response dependent
on the radiation dose of whole body radiation [30,31].
The effects of GHRH or the agonistic analogs are mediated by
the GHRHR. The administration of GHRH antagonists together with
GHRH or its agonistic analogs abolished its protective effects on car-
diomyocytes [19,21]. We believe that GHRH and its receptors have
physiological roles in the recovery from cell injury, and that the
explanation for our ﬁndings in NRVM is the presence and function
of the GHRHR. Granata et al. have demonstrated both the mRNA and
protein expression of the pGHRHR in cardiac cells [19]. The pGHRHR
has been detected in rat hearts by means of Western blotting,
immunohistochemistry and ligand binding assay [24]. In consis-
tence with these ﬁndings, we  showed the presence of a 52 kDa
protein isoform of GHRHR, with Western blotting; the expression
of this protein declined by time in irradiated NRVM, irrespective
of whether JI-34 treatment was  applied. The difference irradiation
made, may  point to the role of the GHRH system in cell recovery
after radiation injury.
In conclusion, the present study provides a well-reproducible
in vitro cell culture model for the investigation of irradiation-
induced cardiomyocyte damage, in which GHRH analogs have been
tested. GHRH agonistic analogs, JI-34 and MR-356 exerted protec-
tive effects on radiation-induced cell damage, hence GHRH agonists
should be tested in vivo as potential protective agents against radio-
genic heart damage.
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